Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma
Ophthalmology Volume 130, Number 6, June 2023
本研究旨在驗證基因表達譜（gene expression profile, GEP）測試在葡萄膜黑色素瘤(Uveal melanoma)患者中的預後價值，並確定將腫瘤大小與GEP分類相結合是否提供額外的預後價值。該研究納入了3 centers including Yale New Haven Hospital, University of California, San Diego; and Memorial Sloan Kettering Cancer Center的脈絡膜黑色素瘤患者。研究發現，腫瘤厚度的預後價值優於GEP分類。GEP 2級腫瘤的轉移率低於Castle Bioscience報告的估計值，而GEP 1A和1B級腫瘤之間的轉移率沒有差異。該研究建議在預測預後時應考慮腫瘤大小和GEP分類，並且GEP 1A或1B級腫瘤的患者可能從相同的轉移監測方案中受益。
This study aimed to validate the prognostic usefulness of gene expression profile (GEP) testing in patients with uveal melanoma and determine whether combining tumor size with GEP classification provides additional prognostic value. The study included patients with choroidal melanoma at Yale New Haven Hospital, University of California, San Diego; and Memorial Sloan Kettering Cancer Center. Tumor thickness was found to have better prognostic usefulness than GEP classification. The rates of metastasis for GEP class 2 tumors were lower than estimates reported by Castle Bioscience, and no difference in metastasis rates was found between GEP class 1A and 1B tumors. The study suggests that tumor size should be considered along with GEP classification for prognostication and that patients with GEP class 1A or 1B tumors may benefit from the same metastatic surveillance protocols.